nodes	percent_of_prediction	percent_of_DWPC	metapath
Zaleplon—CYP3A7—Sorafenib—thyroid cancer	0.129	0.27	CbGbCtD
Zaleplon—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.129	0.27	CbGbCtD
Zaleplon—CYP3A5—Sorafenib—thyroid cancer	0.0967	0.202	CbGbCtD
Zaleplon—CYP3A4—Vandetanib—thyroid cancer	0.0626	0.131	CbGbCtD
Zaleplon—CYP3A4—Sorafenib—thyroid cancer	0.0377	0.0789	CbGbCtD
Zaleplon—CYP3A4—Doxorubicin—thyroid cancer	0.0229	0.0479	CbGbCtD
Zaleplon—Hypertonia—Epirubicin—thyroid cancer	0.000853	0.00163	CcSEcCtD
Zaleplon—Vaginal infection—Doxorubicin—thyroid cancer	0.00085	0.00163	CcSEcCtD
Zaleplon—Abnormal vision—Epirubicin—thyroid cancer	0.000849	0.00162	CcSEcCtD
Zaleplon—Neuropathy—Doxorubicin—thyroid cancer	0.000845	0.00162	CcSEcCtD
Zaleplon—Mental disability—Epirubicin—thyroid cancer	0.000844	0.00162	CcSEcCtD
Zaleplon—Dyspnoea—Sorafenib—thyroid cancer	0.000838	0.0016	CcSEcCtD
Zaleplon—Dry eye—Doxorubicin—thyroid cancer	0.000832	0.00159	CcSEcCtD
Zaleplon—Lymphadenopathy—Epirubicin—thyroid cancer	0.000828	0.00158	CcSEcCtD
Zaleplon—Nausea—Vandetanib—thyroid cancer	0.000827	0.00158	CcSEcCtD
Zaleplon—Dyspepsia—Sorafenib—thyroid cancer	0.000827	0.00158	CcSEcCtD
Zaleplon—Oesophagitis—Doxorubicin—thyroid cancer	0.000823	0.00157	CcSEcCtD
Zaleplon—Rash maculo-papular—Doxorubicin—thyroid cancer	0.000818	0.00157	CcSEcCtD
Zaleplon—Decreased appetite—Sorafenib—thyroid cancer	0.000817	0.00156	CcSEcCtD
Zaleplon—Thrombophlebitis—Epirubicin—thyroid cancer	0.000816	0.00156	CcSEcCtD
Zaleplon—Mouth ulceration—Doxorubicin—thyroid cancer	0.000814	0.00156	CcSEcCtD
Zaleplon—Ecchymosis—Doxorubicin—thyroid cancer	0.000814	0.00156	CcSEcCtD
Zaleplon—Bladder pain—Doxorubicin—thyroid cancer	0.000814	0.00156	CcSEcCtD
Zaleplon—Diabetes mellitus—Epirubicin—thyroid cancer	0.000812	0.00155	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000811	0.00155	CcSEcCtD
Zaleplon—Photosensitivity—Epirubicin—thyroid cancer	0.000804	0.00154	CcSEcCtD
Zaleplon—Pain—Sorafenib—thyroid cancer	0.000803	0.00154	CcSEcCtD
Zaleplon—Constipation—Sorafenib—thyroid cancer	0.000803	0.00154	CcSEcCtD
Zaleplon—Vascular purpura—Epirubicin—thyroid cancer	0.00079	0.00151	CcSEcCtD
Zaleplon—Hypertonia—Doxorubicin—thyroid cancer	0.000789	0.00151	CcSEcCtD
Zaleplon—Eczema—Epirubicin—thyroid cancer	0.000786	0.0015	CcSEcCtD
Zaleplon—Abnormal vision—Doxorubicin—thyroid cancer	0.000785	0.0015	CcSEcCtD
Zaleplon—Eye pain—Epirubicin—thyroid cancer	0.000782	0.0015	CcSEcCtD
Zaleplon—Mental disability—Doxorubicin—thyroid cancer	0.000781	0.0015	CcSEcCtD
Zaleplon—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000768	0.00147	CcSEcCtD
Zaleplon—Lymphadenopathy—Doxorubicin—thyroid cancer	0.000766	0.00147	CcSEcCtD
Zaleplon—Thrombophlebitis—Doxorubicin—thyroid cancer	0.000755	0.00145	CcSEcCtD
Zaleplon—Increased appetite—Epirubicin—thyroid cancer	0.000752	0.00144	CcSEcCtD
Zaleplon—Diabetes mellitus—Doxorubicin—thyroid cancer	0.000751	0.00144	CcSEcCtD
Zaleplon—Urticaria—Sorafenib—thyroid cancer	0.000746	0.00143	CcSEcCtD
Zaleplon—Photosensitivity—Doxorubicin—thyroid cancer	0.000744	0.00142	CcSEcCtD
Zaleplon—Abdominal pain—Sorafenib—thyroid cancer	0.000743	0.00142	CcSEcCtD
Zaleplon—Body temperature increased—Sorafenib—thyroid cancer	0.000743	0.00142	CcSEcCtD
Zaleplon—Dermatitis bullous—Epirubicin—thyroid cancer	0.000739	0.00141	CcSEcCtD
Zaleplon—Purpura—Epirubicin—thyroid cancer	0.000733	0.0014	CcSEcCtD
Zaleplon—Vascular purpura—Doxorubicin—thyroid cancer	0.000731	0.0014	CcSEcCtD
Zaleplon—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.00073	0.0014	CcSEcCtD
Zaleplon—Eczema—Doxorubicin—thyroid cancer	0.000727	0.00139	CcSEcCtD
Zaleplon—Eye pain—Doxorubicin—thyroid cancer	0.000724	0.00139	CcSEcCtD
Zaleplon—Hypoglycaemia—Epirubicin—thyroid cancer	0.000724	0.00139	CcSEcCtD
Zaleplon—Osteoarthritis—Epirubicin—thyroid cancer	0.000706	0.00135	CcSEcCtD
Zaleplon—Diplopia—Epirubicin—thyroid cancer	0.000706	0.00135	CcSEcCtD
Zaleplon—Increased appetite—Doxorubicin—thyroid cancer	0.000696	0.00133	CcSEcCtD
Zaleplon—Affect lability—Epirubicin—thyroid cancer	0.000695	0.00133	CcSEcCtD
Zaleplon—Migraine—Epirubicin—thyroid cancer	0.000695	0.00133	CcSEcCtD
Zaleplon—Dermatitis bullous—Doxorubicin—thyroid cancer	0.000684	0.00131	CcSEcCtD
Zaleplon—Face oedema—Epirubicin—thyroid cancer	0.000682	0.00131	CcSEcCtD
Zaleplon—Purpura—Doxorubicin—thyroid cancer	0.000678	0.0013	CcSEcCtD
Zaleplon—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000675	0.00129	CcSEcCtD
Zaleplon—Asthenia—Sorafenib—thyroid cancer	0.000674	0.00129	CcSEcCtD
Zaleplon—Hypoglycaemia—Doxorubicin—thyroid cancer	0.00067	0.00128	CcSEcCtD
Zaleplon—Mood swings—Epirubicin—thyroid cancer	0.000669	0.00128	CcSEcCtD
Zaleplon—Pruritus—Sorafenib—thyroid cancer	0.000665	0.00127	CcSEcCtD
Zaleplon—Ataxia—Epirubicin—thyroid cancer	0.000664	0.00127	CcSEcCtD
Zaleplon—Diplopia—Doxorubicin—thyroid cancer	0.000654	0.00125	CcSEcCtD
Zaleplon—Osteoarthritis—Doxorubicin—thyroid cancer	0.000654	0.00125	CcSEcCtD
Zaleplon—Liver function test abnormal—Epirubicin—thyroid cancer	0.000652	0.00125	CcSEcCtD
Zaleplon—Dry skin—Epirubicin—thyroid cancer	0.000647	0.00124	CcSEcCtD
Zaleplon—Orthostatic hypotension—Epirubicin—thyroid cancer	0.000645	0.00123	CcSEcCtD
Zaleplon—Affect lability—Doxorubicin—thyroid cancer	0.000643	0.00123	CcSEcCtD
Zaleplon—Migraine—Doxorubicin—thyroid cancer	0.000643	0.00123	CcSEcCtD
Zaleplon—Breast disorder—Epirubicin—thyroid cancer	0.000638	0.00122	CcSEcCtD
Zaleplon—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000636	0.00122	CcSEcCtD
Zaleplon—Face oedema—Doxorubicin—thyroid cancer	0.000631	0.00121	CcSEcCtD
Zaleplon—Gastritis—Epirubicin—thyroid cancer	0.000625	0.0012	CcSEcCtD
Zaleplon—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000623	0.00119	CcSEcCtD
Zaleplon—Muscular weakness—Epirubicin—thyroid cancer	0.000623	0.00119	CcSEcCtD
Zaleplon—Dizziness—Sorafenib—thyroid cancer	0.000621	0.00119	CcSEcCtD
Zaleplon—Mood swings—Doxorubicin—thyroid cancer	0.000619	0.00119	CcSEcCtD
Zaleplon—Ataxia—Doxorubicin—thyroid cancer	0.000615	0.00118	CcSEcCtD
Zaleplon—Dysphagia—Epirubicin—thyroid cancer	0.000611	0.00117	CcSEcCtD
Zaleplon—Asthma—Epirubicin—thyroid cancer	0.000611	0.00117	CcSEcCtD
Zaleplon—Eosinophilia—Epirubicin—thyroid cancer	0.000604	0.00116	CcSEcCtD
Zaleplon—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000603	0.00116	CcSEcCtD
Zaleplon—Dry skin—Doxorubicin—thyroid cancer	0.000599	0.00115	CcSEcCtD
Zaleplon—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000597	0.00114	CcSEcCtD
Zaleplon—Angina pectoris—Epirubicin—thyroid cancer	0.000595	0.00114	CcSEcCtD
Zaleplon—Rash—Sorafenib—thyroid cancer	0.000592	0.00113	CcSEcCtD
Zaleplon—Dermatitis—Sorafenib—thyroid cancer	0.000592	0.00113	CcSEcCtD
Zaleplon—Breast disorder—Doxorubicin—thyroid cancer	0.000591	0.00113	CcSEcCtD
Zaleplon—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000589	0.00113	CcSEcCtD
Zaleplon—Headache—Sorafenib—thyroid cancer	0.000589	0.00113	CcSEcCtD
Zaleplon—Bronchitis—Epirubicin—thyroid cancer	0.000587	0.00112	CcSEcCtD
Zaleplon—Gastritis—Doxorubicin—thyroid cancer	0.000578	0.00111	CcSEcCtD
Zaleplon—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000576	0.0011	CcSEcCtD
Zaleplon—Muscular weakness—Doxorubicin—thyroid cancer	0.000576	0.0011	CcSEcCtD
Zaleplon—Dysuria—Epirubicin—thyroid cancer	0.000571	0.00109	CcSEcCtD
Zaleplon—Dysphagia—Doxorubicin—thyroid cancer	0.000565	0.00108	CcSEcCtD
Zaleplon—Asthma—Doxorubicin—thyroid cancer	0.000565	0.00108	CcSEcCtD
Zaleplon—Pollakiuria—Epirubicin—thyroid cancer	0.000564	0.00108	CcSEcCtD
Zaleplon—Eosinophilia—Doxorubicin—thyroid cancer	0.000559	0.00107	CcSEcCtD
Zaleplon—Nausea—Sorafenib—thyroid cancer	0.000558	0.00107	CcSEcCtD
Zaleplon—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000557	0.00107	CcSEcCtD
Zaleplon—Weight increased—Epirubicin—thyroid cancer	0.000556	0.00106	CcSEcCtD
Zaleplon—Weight decreased—Epirubicin—thyroid cancer	0.000552	0.00106	CcSEcCtD
Zaleplon—Hyperglycaemia—Epirubicin—thyroid cancer	0.000551	0.00105	CcSEcCtD
Zaleplon—Angina pectoris—Doxorubicin—thyroid cancer	0.00055	0.00105	CcSEcCtD
Zaleplon—Pneumonia—Epirubicin—thyroid cancer	0.000548	0.00105	CcSEcCtD
Zaleplon—Bronchitis—Doxorubicin—thyroid cancer	0.000543	0.00104	CcSEcCtD
Zaleplon—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000534	0.00102	CcSEcCtD
Zaleplon—Stomatitis—Epirubicin—thyroid cancer	0.000531	0.00102	CcSEcCtD
Zaleplon—Conjunctivitis—Epirubicin—thyroid cancer	0.000529	0.00101	CcSEcCtD
Zaleplon—Dysuria—Doxorubicin—thyroid cancer	0.000528	0.00101	CcSEcCtD
Zaleplon—Sweating—Epirubicin—thyroid cancer	0.000522	0.000999	CcSEcCtD
Zaleplon—Pollakiuria—Doxorubicin—thyroid cancer	0.000522	0.000999	CcSEcCtD
Zaleplon—Haematuria—Epirubicin—thyroid cancer	0.000519	0.000994	CcSEcCtD
Zaleplon—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000516	0.000987	CcSEcCtD
Zaleplon—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000515	0.000985	CcSEcCtD
Zaleplon—Weight increased—Doxorubicin—thyroid cancer	0.000514	0.000984	CcSEcCtD
Zaleplon—Epistaxis—Epirubicin—thyroid cancer	0.000513	0.000983	CcSEcCtD
Zaleplon—Weight decreased—Doxorubicin—thyroid cancer	0.000511	0.000978	CcSEcCtD
Zaleplon—Hyperglycaemia—Doxorubicin—thyroid cancer	0.00051	0.000975	CcSEcCtD
Zaleplon—Pneumonia—Doxorubicin—thyroid cancer	0.000507	0.00097	CcSEcCtD
Zaleplon—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000494	0.000945	CcSEcCtD
Zaleplon—Stomatitis—Doxorubicin—thyroid cancer	0.000491	0.00094	CcSEcCtD
Zaleplon—Conjunctivitis—Doxorubicin—thyroid cancer	0.00049	0.000937	CcSEcCtD
Zaleplon—Hypoaesthesia—Epirubicin—thyroid cancer	0.000486	0.000931	CcSEcCtD
Zaleplon—Sweating—Doxorubicin—thyroid cancer	0.000483	0.000924	CcSEcCtD
Zaleplon—Oedema peripheral—Epirubicin—thyroid cancer	0.000481	0.000922	CcSEcCtD
Zaleplon—Haematuria—Doxorubicin—thyroid cancer	0.00048	0.000919	CcSEcCtD
Zaleplon—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000476	0.000912	CcSEcCtD
Zaleplon—Epistaxis—Doxorubicin—thyroid cancer	0.000475	0.000909	CcSEcCtD
Zaleplon—Visual impairment—Epirubicin—thyroid cancer	0.000471	0.000901	CcSEcCtD
Zaleplon—Eye disorder—Epirubicin—thyroid cancer	0.000457	0.000874	CcSEcCtD
Zaleplon—Tinnitus—Epirubicin—thyroid cancer	0.000456	0.000872	CcSEcCtD
Zaleplon—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00045	0.000861	CcSEcCtD
Zaleplon—Oedema peripheral—Doxorubicin—thyroid cancer	0.000445	0.000853	CcSEcCtD
Zaleplon—Immune system disorder—Epirubicin—thyroid cancer	0.000441	0.000845	CcSEcCtD
Zaleplon—Chills—Epirubicin—thyroid cancer	0.000438	0.000839	CcSEcCtD
Zaleplon—Visual impairment—Doxorubicin—thyroid cancer	0.000436	0.000834	CcSEcCtD
Zaleplon—Alopecia—Epirubicin—thyroid cancer	0.000432	0.000827	CcSEcCtD
Zaleplon—Mental disorder—Epirubicin—thyroid cancer	0.000428	0.00082	CcSEcCtD
Zaleplon—Malnutrition—Epirubicin—thyroid cancer	0.000425	0.000814	CcSEcCtD
Zaleplon—Eye disorder—Doxorubicin—thyroid cancer	0.000423	0.000809	CcSEcCtD
Zaleplon—Tinnitus—Doxorubicin—thyroid cancer	0.000422	0.000807	CcSEcCtD
Zaleplon—Flatulence—Epirubicin—thyroid cancer	0.000419	0.000802	CcSEcCtD
Zaleplon—Tension—Epirubicin—thyroid cancer	0.000417	0.000799	CcSEcCtD
Zaleplon—Dysgeusia—Epirubicin—thyroid cancer	0.000417	0.000797	CcSEcCtD
Zaleplon—Nervousness—Epirubicin—thyroid cancer	0.000413	0.000791	CcSEcCtD
Zaleplon—Back pain—Epirubicin—thyroid cancer	0.000411	0.000788	CcSEcCtD
Zaleplon—Immune system disorder—Doxorubicin—thyroid cancer	0.000408	0.000782	CcSEcCtD
Zaleplon—Chills—Doxorubicin—thyroid cancer	0.000406	0.000777	CcSEcCtD
Zaleplon—Alopecia—Doxorubicin—thyroid cancer	0.0004	0.000765	CcSEcCtD
Zaleplon—Mental disorder—Doxorubicin—thyroid cancer	0.000396	0.000758	CcSEcCtD
Zaleplon—Ill-defined disorder—Epirubicin—thyroid cancer	0.000395	0.000756	CcSEcCtD
Zaleplon—Malnutrition—Doxorubicin—thyroid cancer	0.000394	0.000753	CcSEcCtD
Zaleplon—Anaemia—Epirubicin—thyroid cancer	0.000393	0.000753	CcSEcCtD
Zaleplon—Agitation—Epirubicin—thyroid cancer	0.000391	0.000748	CcSEcCtD
Zaleplon—Flatulence—Doxorubicin—thyroid cancer	0.000388	0.000742	CcSEcCtD
Zaleplon—Tension—Doxorubicin—thyroid cancer	0.000386	0.000739	CcSEcCtD
Zaleplon—Dysgeusia—Doxorubicin—thyroid cancer	0.000385	0.000738	CcSEcCtD
Zaleplon—Malaise—Epirubicin—thyroid cancer	0.000384	0.000734	CcSEcCtD
Zaleplon—Nervousness—Doxorubicin—thyroid cancer	0.000382	0.000732	CcSEcCtD
Zaleplon—Vertigo—Epirubicin—thyroid cancer	0.000382	0.000732	CcSEcCtD
Zaleplon—Syncope—Epirubicin—thyroid cancer	0.000381	0.00073	CcSEcCtD
Zaleplon—Back pain—Doxorubicin—thyroid cancer	0.000381	0.000729	CcSEcCtD
Zaleplon—Palpitations—Epirubicin—thyroid cancer	0.000376	0.00072	CcSEcCtD
Zaleplon—Loss of consciousness—Epirubicin—thyroid cancer	0.000374	0.000716	CcSEcCtD
Zaleplon—Hypertension—Epirubicin—thyroid cancer	0.000367	0.000703	CcSEcCtD
Zaleplon—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000365	0.000699	CcSEcCtD
Zaleplon—Anaemia—Doxorubicin—thyroid cancer	0.000364	0.000696	CcSEcCtD
Zaleplon—Arthralgia—Epirubicin—thyroid cancer	0.000362	0.000693	CcSEcCtD
Zaleplon—Chest pain—Epirubicin—thyroid cancer	0.000362	0.000693	CcSEcCtD
Zaleplon—Myalgia—Epirubicin—thyroid cancer	0.000362	0.000693	CcSEcCtD
Zaleplon—Agitation—Doxorubicin—thyroid cancer	0.000362	0.000692	CcSEcCtD
Zaleplon—Anxiety—Epirubicin—thyroid cancer	0.000361	0.000691	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00036	0.000688	CcSEcCtD
Zaleplon—Discomfort—Epirubicin—thyroid cancer	0.000358	0.000685	CcSEcCtD
Zaleplon—Malaise—Doxorubicin—thyroid cancer	0.000355	0.000679	CcSEcCtD
Zaleplon—Dry mouth—Epirubicin—thyroid cancer	0.000354	0.000678	CcSEcCtD
Zaleplon—Vertigo—Doxorubicin—thyroid cancer	0.000354	0.000677	CcSEcCtD
Zaleplon—Syncope—Doxorubicin—thyroid cancer	0.000353	0.000676	CcSEcCtD
Zaleplon—Confusional state—Epirubicin—thyroid cancer	0.00035	0.00067	CcSEcCtD
Zaleplon—Palpitations—Doxorubicin—thyroid cancer	0.000348	0.000666	CcSEcCtD
Zaleplon—Anaphylactic shock—Epirubicin—thyroid cancer	0.000347	0.000665	CcSEcCtD
Zaleplon—Oedema—Epirubicin—thyroid cancer	0.000347	0.000665	CcSEcCtD
Zaleplon—Loss of consciousness—Doxorubicin—thyroid cancer	0.000346	0.000662	CcSEcCtD
Zaleplon—Shock—Epirubicin—thyroid cancer	0.000342	0.000654	CcSEcCtD
Zaleplon—Nervous system disorder—Epirubicin—thyroid cancer	0.00034	0.000652	CcSEcCtD
Zaleplon—Hypertension—Doxorubicin—thyroid cancer	0.00034	0.000651	CcSEcCtD
Zaleplon—Tachycardia—Epirubicin—thyroid cancer	0.000339	0.000649	CcSEcCtD
Zaleplon—Skin disorder—Epirubicin—thyroid cancer	0.000337	0.000646	CcSEcCtD
Zaleplon—Hyperhidrosis—Epirubicin—thyroid cancer	0.000336	0.000642	CcSEcCtD
Zaleplon—Myalgia—Doxorubicin—thyroid cancer	0.000335	0.000641	CcSEcCtD
Zaleplon—Chest pain—Doxorubicin—thyroid cancer	0.000335	0.000641	CcSEcCtD
Zaleplon—Arthralgia—Doxorubicin—thyroid cancer	0.000335	0.000641	CcSEcCtD
Zaleplon—Anxiety—Doxorubicin—thyroid cancer	0.000334	0.000639	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000333	0.000637	CcSEcCtD
Zaleplon—Discomfort—Doxorubicin—thyroid cancer	0.000331	0.000634	CcSEcCtD
Zaleplon—Anorexia—Epirubicin—thyroid cancer	0.000331	0.000633	CcSEcCtD
Zaleplon—Dry mouth—Doxorubicin—thyroid cancer	0.000328	0.000627	CcSEcCtD
Zaleplon—Hypotension—Epirubicin—thyroid cancer	0.000324	0.000621	CcSEcCtD
Zaleplon—Confusional state—Doxorubicin—thyroid cancer	0.000324	0.00062	CcSEcCtD
Zaleplon—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000321	0.000615	CcSEcCtD
Zaleplon—Oedema—Doxorubicin—thyroid cancer	0.000321	0.000615	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000316	0.000605	CcSEcCtD
Zaleplon—Shock—Doxorubicin—thyroid cancer	0.000316	0.000605	CcSEcCtD
Zaleplon—Nervous system disorder—Doxorubicin—thyroid cancer	0.000315	0.000603	CcSEcCtD
Zaleplon—Insomnia—Epirubicin—thyroid cancer	0.000314	0.000601	CcSEcCtD
Zaleplon—Tachycardia—Doxorubicin—thyroid cancer	0.000314	0.0006	CcSEcCtD
Zaleplon—Skin disorder—Doxorubicin—thyroid cancer	0.000312	0.000597	CcSEcCtD
Zaleplon—Paraesthesia—Epirubicin—thyroid cancer	0.000312	0.000597	CcSEcCtD
Zaleplon—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000311	0.000594	CcSEcCtD
Zaleplon—Dyspnoea—Epirubicin—thyroid cancer	0.00031	0.000593	CcSEcCtD
Zaleplon—Somnolence—Epirubicin—thyroid cancer	0.000309	0.000591	CcSEcCtD
Zaleplon—Anorexia—Doxorubicin—thyroid cancer	0.000306	0.000586	CcSEcCtD
Zaleplon—Dyspepsia—Epirubicin—thyroid cancer	0.000306	0.000585	CcSEcCtD
Zaleplon—Decreased appetite—Epirubicin—thyroid cancer	0.000302	0.000578	CcSEcCtD
Zaleplon—Hypotension—Doxorubicin—thyroid cancer	0.0003	0.000575	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.0003	0.000574	CcSEcCtD
Zaleplon—Constipation—Epirubicin—thyroid cancer	0.000297	0.000568	CcSEcCtD
Zaleplon—Pain—Epirubicin—thyroid cancer	0.000297	0.000568	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000293	0.00056	CcSEcCtD
Zaleplon—Insomnia—Doxorubicin—thyroid cancer	0.000291	0.000556	CcSEcCtD
Zaleplon—Paraesthesia—Doxorubicin—thyroid cancer	0.000288	0.000552	CcSEcCtD
Zaleplon—Dyspnoea—Doxorubicin—thyroid cancer	0.000286	0.000548	CcSEcCtD
Zaleplon—Feeling abnormal—Epirubicin—thyroid cancer	0.000286	0.000548	CcSEcCtD
Zaleplon—Somnolence—Doxorubicin—thyroid cancer	0.000286	0.000547	CcSEcCtD
Zaleplon—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000284	0.000543	CcSEcCtD
Zaleplon—Dyspepsia—Doxorubicin—thyroid cancer	0.000283	0.000541	CcSEcCtD
Zaleplon—Decreased appetite—Doxorubicin—thyroid cancer	0.000279	0.000535	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000277	0.000531	CcSEcCtD
Zaleplon—Urticaria—Epirubicin—thyroid cancer	0.000276	0.000528	CcSEcCtD
Zaleplon—Constipation—Doxorubicin—thyroid cancer	0.000275	0.000526	CcSEcCtD
Zaleplon—Pain—Doxorubicin—thyroid cancer	0.000275	0.000526	CcSEcCtD
Zaleplon—Body temperature increased—Epirubicin—thyroid cancer	0.000274	0.000525	CcSEcCtD
Zaleplon—Abdominal pain—Epirubicin—thyroid cancer	0.000274	0.000525	CcSEcCtD
Zaleplon—Feeling abnormal—Doxorubicin—thyroid cancer	0.000265	0.000507	CcSEcCtD
Zaleplon—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000263	0.000503	CcSEcCtD
Zaleplon—Urticaria—Doxorubicin—thyroid cancer	0.000255	0.000489	CcSEcCtD
Zaleplon—Abdominal pain—Doxorubicin—thyroid cancer	0.000254	0.000486	CcSEcCtD
Zaleplon—Body temperature increased—Doxorubicin—thyroid cancer	0.000254	0.000486	CcSEcCtD
Zaleplon—Asthenia—Epirubicin—thyroid cancer	0.000249	0.000477	CcSEcCtD
Zaleplon—Pruritus—Epirubicin—thyroid cancer	0.000246	0.00047	CcSEcCtD
Zaleplon—Asthenia—Doxorubicin—thyroid cancer	0.00023	0.000441	CcSEcCtD
Zaleplon—Dizziness—Epirubicin—thyroid cancer	0.00023	0.000439	CcSEcCtD
Zaleplon—Pruritus—Doxorubicin—thyroid cancer	0.000227	0.000435	CcSEcCtD
Zaleplon—Rash—Epirubicin—thyroid cancer	0.000219	0.000419	CcSEcCtD
Zaleplon—Dermatitis—Epirubicin—thyroid cancer	0.000219	0.000419	CcSEcCtD
Zaleplon—Headache—Epirubicin—thyroid cancer	0.000217	0.000416	CcSEcCtD
Zaleplon—Dizziness—Doxorubicin—thyroid cancer	0.000212	0.000407	CcSEcCtD
Zaleplon—Nausea—Epirubicin—thyroid cancer	0.000206	0.000395	CcSEcCtD
Zaleplon—Rash—Doxorubicin—thyroid cancer	0.000203	0.000388	CcSEcCtD
Zaleplon—Dermatitis—Doxorubicin—thyroid cancer	0.000202	0.000387	CcSEcCtD
Zaleplon—Headache—Doxorubicin—thyroid cancer	0.000201	0.000385	CcSEcCtD
Zaleplon—Nausea—Doxorubicin—thyroid cancer	0.000191	0.000365	CcSEcCtD
